Replication-defective mutant strains of herpes simplex virus (HSV) induce immune responses that are as durable as those of replication-competent HSV strains (7, 30) . This continues to be paradoxical because several studies have shown that replication-defective HSV strains do not spread efficiently to sensory ganglia and establish latent infection to only a very low level (12, 16, 17, 21) . In addition, replication-defective HSV mutants express many viral proteins (9, 10) but do not generate infectious progeny virus. Regardless, they are immunogenic in animal models (6, 9, 12, 29) , including rhesus macaques (32), and elicit protection against virulent HSV challenge (5, 6, 10, 25, 26, 28, 29) . A recent comparison of herpes vaccine candidates in mice indicated that replication-defective HSV strains were more effective than glycoprotein-or DNA-based modalities (16). A complete understanding of the mechanisms by which long-term immune responses are induced by these replication-defective vectors, and viral vaccines in general, is necessary and remains an important area of investigation.
Replication-defective mutant strains of herpes simplex virus (HSV) induce immune responses that are as durable as those of replication-competent HSV strains (7, 30) . This continues to be paradoxical because several studies have shown that replication-defective HSV strains do not spread efficiently to sensory ganglia and establish latent infection to only a very low level (12, 16, 17, 21) . In addition, replication-defective HSV mutants express many viral proteins (9, 10) but do not generate infectious progeny virus. Regardless, they are immunogenic in animal models (6, 9, 12, 29) , including rhesus macaques (32) , and elicit protection against virulent HSV challenge (5, 6, 10, 25, 26, 28, 29) . A recent comparison of herpes vaccine candidates in mice indicated that replication-defective HSV strains were more effective than glycoprotein-or DNA-based modalities (16) . A complete understanding of the mechanisms by which long-term immune responses are induced by these replication-defective vectors, and viral vaccines in general, is necessary and remains an important area of investigation.
Antibody responses following many viral infections are very long lived, and several mechanisms for maintenance of serum immunoglobulin G (IgG) have been described. Lymphocytic choriomeningitis virus infection generates professional antibody-producing plasma cells (PCs) that traffic to the bone marrow and whose survival appears to be independent of antigen (23) . Antigen independence was also observed using an experimental Cre-lox system to alter the specificities of memory B cells in vivo (24) . Thus, B-cell memory has been considered by some to be antigen independent. In vesicular stomatitis virus-infected mice, long-lived germinal centers and IgG responses have been associated with antigen retention on follicular dendritic cells (FDC) (2, 3) , likely in the form of immune complexes of antigen that is opsonized with antibody and complement. Therefore, retention of immune complexes on FDC can be mediated by complement receptor (Cr) CD21 or CD35 (1, 13, 36) or Fc gamma receptor II (33, 39) and presumably allows continued restimulation of memory B cells. Thus, some have argued that antigen is necessary for optimal IgG responses.
In mice, complement receptors CD21 and CD35 are splice variants encoded by a single gene, Cr2, and transgenic mice disrupted for this locus (Cr2 Ϫ/Ϫ ) have been generated (1, 13, 27) . The role of CD21/CD35 in antigen retention and antibody durability has been investigated previously through the use of radiation chimera approaches in which bone marrow cells were transplanted into irradiated wild-type (WT) or Cr2 Ϫ/Ϫ animals (13) or through adoptive transfer studies where antigen-primed cells were injected into naïve WT or Cr2 Ϫ/Ϫ mice (4). In these systems, B cells expressed CD21/CD35, whereas stromal cells were deficient for these receptors, or vice versa. Using either methodology, signaling of the CD21/CD35 receptor on B cells was required to generate a short-term IgG response to purified protein antigen delivered systemically, but long-term maintenance of serum IgG required expression of Cr2 on stromal cells, such as FDC.
To investigate the mechanism by which immunization with replication-defective HSV induces durable immunity, we evaluated the antiviral IgG response in mice. We observed that the HSV protein specificities of the IgG response shifted over time, suggesting that the humoral response continued to evolve several months postinfection. To assess the role of antigen retention in this setting, we used a radiation-chimeric mouse model. In mice where CD21/CD35 was absent on stromal cells, antiviral serum IgG titers declined rapidly and recall responses to HSV were lost. We conclude that optimal maintenance of IgG responses following replication-defective HSV infection requires expression of CD21/CD35 on stromal cells.
MATERIALS AND METHODS

Cells and viruses.
Vero cells (CCL-81; American Type Culture Collection) containing the HSV-2 U L 5 and HSV-1 U L 29 genes (V5-29 cells) have been described previously (10) . Cells were grown in Dulbecco's modified Eagle's medium (DMEM; Cellgro) supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM L-glutamine, 400 g/ml G418, and 10% bovine calf serum (vol/vol) (DMEM-10) at 37°C with 5% CO 2 . Following viral infection, cells were maintained in DMEM containing penicillin, streptomycin, L-glutamine, and 1% bovine calf serum (vol/vol) (DMEM-V) at 34°C until harvest.
Replication-defective HSV-2 strains dl5, dl29 (9, 12) , and 5BlacZ (10) have been described previously. The dl5 mutant was generated from the HSV-2 186 WT strain by deletion of the U L 5 gene. U L 5 is an essential component of the viral helicase-primase complex and is required for viral DNA synthesis. The dl29 mutant was generated in the 186 strain by deletion of the U L 29 gene, which encodes the viral single-stranded DNA binding protein ICP8, which is also essential for viral DNA synthesis. The 5BlacZ mutant was generated from the 186 strain by replacing the U L 29 gene (ICP8 protein) with a fusion protein that contains the N-terminal 288 amino acids of ICP8 fused to the Escherichia coli ␤-galactosidase protein. All viruses were propagated on a complementing Veroderived cell line, V5-29, which expresses the U L 5 and U L 29 gene products. Stocks of cell-free virus were prepared and their titers determined using V5-29 cells as described previously (19) , and they were verified to be replication defective by titration on noncomplementing Vero cells. The attenuated, replication-competent HSV-2 186⌬Kpn strain contains a deletion in the viral thymidine kinase (TK) gene (17) and was used in some experiments to compare the persistence levels of viral DNA following immunization. This virus was grown and its titer was determined using Vero cells.
Mice and bone marrow chimera construction. BALB/cJ mice were purchased from Jackson Laboratories (Bar Harbor, ME) and used for the experiments shown in Fig. 2 and 3 . C57BL/6 mice (CD45.1 allotype) served as WT controls and bone marrow donors for the generation of radiation chimeras (see Fig. 4 ). Mice deficient in complement receptors CD21 and CD35 (Cr2 Ϫ/Ϫ ), maintained on a C57BL/6 background (CD45.2 allotype), were used as controls and bone marrow recipients for radiation chimeras. C57BL/6 and Cr2 Ϫ/Ϫ mice were bred in-house at Harvard Medical School. Radiation chimeras were generated as described previously (38) . Briefly, 6-week-old mice were lethally irradiated (2 ϫ 650 rads from a cesium-137 source), anesthetized by isoflurane inhalation (Abbott Laboratories), infused with 1 ϫ 10 7 WT bone marrow cells, and rested for 6 weeks prior to the experiments. Bone marrow chimeras were evaluated by measuring the percentage of CD45.1-positive peripheral blood mononuclear cells using flow cytometry. Successful chimeras were defined as animals with at least 95% donor bone marrow-derived peripheral blood mononuclear cells. All mice were housed at Harvard Medical School in a specific-pathogen-free facility. Study procedures complied with NIH guidelines and institutional reviews by the CBR Institute and Harvard Medical School Animal Care and Use committees.
Virus inoculations. Mice were inoculated by either the subcutaneous (s.c.), the intramuscular (i.m.), or the intraperitoneal (i.p.) route using a dose of 2 ϫ 10 6 PFU of virus in a 20-l volume prepared by dilution in sterile, endotoxin-free saline (Sigma). For initial experiments, groups of BALB/cJ mice were inoculated s.c. at week 0 with either dl5 or dl29. At weeks 4 and 8, all mice were inoculated s.c. with 5BlacZ. This immunization strategy reproducibly elicits protection against challenge infection and induces robust and durable IgG responses (7, 29) . For radiation chimera experiments, C57BL/6 (WT), Cr2
Ϫ/Ϫ mice reconstituted with WT bone marrow (WTBM3Cr2 Ϫ/Ϫ ) or untreated Cr2 Ϫ/Ϫ control mice were infected by the i.m. route using a dose of 2 ϫ 10 6 PFU of 5BlacZ at weeks 0, 4, and 8. Recall responses in these mice were measured following i.p. inoculation with 5BlacZ at week 32 (6 months following the final immunization). The i.p. route was chosen to elicit maximal stimulation of memory B-cell responses.
Serum collection and ELISA. Blood was collected from each mouse prior to inoculation (week 0) and throughout the course of each experiment by tail vein puncture or retro-orbital bleeding. Sera were prepared using Microtainer brand serum separators (Becton Dickinson) and stored at Ϫ20°C prior to analysis. Enzyme-linked immunosorbent assays (ELISA) to determine antigen-specific IgG titers were completed as described previously (11) . Briefly, 96-well Maxisorp microtiter plates (Nunc) were coated with Triton X-100-treated, cell-free HSV-2 5BlacZ lysate (250 ng total protein/well) in sodium bicarbonate buffer, pH 9.6 (Sigma). Plates were incubated with serial twofold dilutions of sera, and IgG was detected using rabbit anti-mouse IgG antibody conjugated to alkaline phosphatase (1:1,000 dilution; Sigma). Plates were developed with p-nitrophenyl phosphate (Sigma) and read at 405 nm on a microplate reader (Molecular Devices). Antibody titer was calculated as the reciprocal of the final dilution resulting in an optical density at 405 nm 0.2 units above the background (naïve serum) level and is presented as the mean Ϯ standard error of the mean (SEM) for each group.
Western immunoblots. Triton X-100-treated, cell-free 5BlacZ virions (10 g total protein) or Triton X-100-treated, 5BlacZ-infected V5-29 cells (50 g total protein) were fractionated using preparatory gels containing 9.25% N,NЈ-diallyltartardiamide-cross-linked sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and electroblotted to nitrocellulose (PROTRAN, Schleicher and Schuell). Membranes were washed in Tris-buffered saline (pH 7.4) containing 0.1% Tween 20 (TBST) and treated with blocking buffer (TBST containing 5% nonfat milk) for 2 h at 4°C. Serum samples from each group of mice were pooled in equal parts, diluted 1:200 in blocking buffer, and assayed using a Surf-Blot apparatus (Idea Scientific, MN) according to the manufacturer's directions. After incubation at room temperature for 1 h, the membrane was washed in TBST, incubated with secondary rabbit anti-mouse IgG antibody coupled to horseradish peroxidase (1:10,000; Santa Cruz), washed, and detected using enhanced chemiluminescence reagents (Amersham) and Kodak XAR-5 film.
Real-time PCR. HSV-2 DNA was detected in mouse tissues using a sensitive real-time PCR assay based on techniques described previously (17) . Mice were inoculated by the i.m. route with a dose of 2 ϫ 10 6 PFU of 5BlacZ or 186⌬Kpn or mock treated. At 5 months postinfection, the indicated tissues were collected under sterile conditions and frozen at Ϫ80°C prior to processing as described previously (17, 20) . Total genomic DNA was extracted using a DNeasy tissue kit (QIAGEN). HSV DNA was detected using real-time PCR. In brief, TaqMan PCR amplification and detection were performed on an ABI 7700 sequence detector (Applied Biosystems) using the HSV-2 TK gene-specific primers F145 (CTG TTC TTT TAT TGC CGT CAT CG) and R263 (GTC CAT CGC CGA GTA CGC) and the fluorescence-labeled probe TK-pr (6-carboxyfluorescein-TTT GAA CTA AAC TCC CCC CAC CTC GC-6-carboxytetramethylrhodamine). Reactions were performed in a 50-l volume containing 30 ng of DNA and TaqMan universal PCR master mix (Applied Biosystems) with a final concentration of 250 nM of each primer and 200 nM of TaqMan probe and amplified for 40 cycles. For the viral DNA standard, purified HSV-2 186 strain DNA was serially 10-fold diluted (from 10 6 to 1 copy) in the presence of 30 ng genomic DNA isolated from uninfected CV-1 cells. This standard curve indicated that the limit of detection for the assay was one copy.
RESULTS
Replication-defective HSV-2 recombinants elicit durable humoral responses.
We have shown previously that replication-defective HSV-1 mutant viruses elicit durable immunity in mouse models (7, 31) . Because of the potential utility of mutant HSV-2 strains as genital herpes vaccines (9, 12), we wanted to verify these observations using HSV-2 mutant strains. We examined the serum IgG response following immunization with replication-defective HSV-2 mutants derived from WT 186 strain virus that are deleted for either the U L 5 helicase-primase component protein gene (dl5 strain) or the U L 29 single-stranded DNA binding protein gene (dl29 and 5BlacZ strains) (Fig. 1) . Both of these genes are essential for productive HSV infection (10). Mice were inoculated at week 0 by the s.c. route with a dose of 2 ϫ 10 6 PFU of dl5 or dl29. At weeks 4 and 8, all mice were inoculated with a dose of 2 ϫ 10 6 PFU of 5BlacZ. We collected serum from each animal 7112 BROCKMAN ET AL. J. VIROL. every 2 weeks up to week 12 and measured antiviral IgG by ELISA (Fig. 2 ). Primary inoculation with either dl5 or dl29 virus generated a low-titer, anti-HSV IgG response by week 4. Secondary infection with 5BlacZ enhanced responses at weeks 6 and 8, and an additional boost with 5BlacZ further increased antiviral IgG titers by weeks 10 and 12. Unexpectedly, serum titers in the dl5 group were consistently lower than in the dl29-inoculated animals. This may indicate a difference in the ability of these viruses to produce viral antigen and induce primary IgG responses that were apparent only following a secondary exposure using 5BlacZ.
To assess the durability of these responses, we evaluated serum titers in these mice at weeks 16, 20, 30, 44, and 60. We observed that antiviral IgG titers peaked at relatively early times and then declined in all groups but stabilized by week 20 at approximately 30 to 50% of peak titers. Antibody titers were constant for at least 50 weeks postinfection, and these results paralleled our earlier findings of durable IgG antibody responses following inoculation of mice using replication-defective HSV-1 strains (7).
Some IgG responses are enhanced at late times postinfection. Productive HSV infection is characterized by the expression of at least 70 viral proteins. To assess the breadth of the IgG responses in these mice, we evaluated the HSV-2 antigen specificity using Western blot analysis. Pooled sera from the dl29-infected group of mice were used to probe membranes prepared using cell-free HSV-2 virion protein lysate (Fig. 3A) . Despite the fact that ELISA titers remained relatively stable at late times, we observed that the antiviral IgG specificities were not static over this period. Three patterns of antibody responses, which we have labeled "continuous," "declining," and "late/enhanced," were seen in these mice. Continuous IgG responses were usually generated immediately following infection and remained detectable for the duration of the experiment. This type of response could be seen for proteins with molecular masses of ϳ200 kDa and ϳ35 kDa. Declining responses were also induced early following infection but appeared to diminish over time (e.g., for proteins with molecular masses of ϳ180 kDa, ϳ120 kDa, ϳ110 kDa, and ϳ50 kDa). Late/enhanced IgG responses appeared to be significantly improved at later times in the absence of new infection (e.g., for proteins with molecular masses of ϳ70 kDa, ϳ60 kDa, and ϳ40 kDa).
A significant component of the host immune response to HSV is likely to be directed against nonstructural viral proteins that are highly expressed in infected cells and not incorporated efficiently into viral particles. Therefore, we repeated this Western blot analysis using membranes prepared with lysates from HSV-infected V5-29 cells (Fig. 3B) . We observed similar patterns of responses regardless of the source of viral proteins. Continuous IgG responses were directed against proteins with molecular masses of ϳ200 kDa, ϳ110 kDa, ϳ80 kDa, ϳ65 kDa (Fig. 3B , broad band), ϳ60 kDa, and ϳ35 kDa. In addition, a late/enhanced IgG response against one protein with a molecular mass of ϳ55 kDa was observed. Next, we performed similar Western blot analyses using sera from the dl5 group of mice (Fig. 3C) . In addition to several continuous responses in these animals (i.e., for proteins with molecular masses of ϳ110 kDa and 65 kDa), we observed late/enhanced responses to proteins with molecular masses of ϳ60 kDa and ϳ55 kDa. Taken together, these results indicated that the IgG responses evolved over an extended time following immunization with replication-defective HSV mutants. This might be due to maturation of IgG avidity, ongoing isotype class-switch recombination, or delayed expansion of low-magnitude cell populations. Regardless of the mechanism, this observation indicates that sufficient viral antigen may persist following inoculation to drive IgG evolution. We observed similar late/enhanced responses to a subset of viral proteins in both groups of mice, further implying that this result may be a general occurrence following infection with replication-defective HSV vectors. Maintenance of serum IgG requires CD21/CD35 on stromal cells. The apparent ongoing evolution of the humoral immune response indicated that antigen persistence might play an important role in the generation of durable immunity following infection by replication-defective HSV. To address this directly, we used a radiation bone marrow chimera model in which Cr2 ϩ/ϩ myeloid cells were transferred into Cr2 Ϫ/Ϫ mice. We generated chimeric mice by reconstituting irradiated Cr2
Ϫ/Ϫ mice with wild-type bone marrow (WTBM3Cr2 Ϫ/Ϫ ). The induction and durability of HSV-2 specific IgG were measured using ELISA. Groups of mice were inoculated by the s.c. route at week 0 (black triangle) with 2 ϫ 10 6 PFU of either strain dl29 (n ϭ 6) (solid line) or strain dl5 (n ϭ 6) (dashed line). At weeks 4 and 8, all mice were boosted by inoculation with 2 ϫ 10 6 PFU of strain 5BlacZ (white triangles). Sera were collected at the indicated times, and IgG antibody titers were determined. Results are shown as the reciprocals of the mean endpoint dilutions Ϯ SEMs.
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The percentages of chimerism were examined by flow cytometry to distinguish donor cells (CD45.1 positive) from recipient cells (CD45.2 positive) and were greater than 98% in all mice (data not shown). Mice were inoculated at weeks 0, 4, and 8 with a dose of 2 ϫ 10 6 PFU of 5BlacZ virus by the i.m. route. Sera were collected regularly, up to week 32, and antiviral IgG titers were determined using ELISA (Fig. 4A) . Following infection, WT mice elicited IgG responses at weeks 3 through 10 that were similar in kinetics and magnitude to those in previous experiments (Fig. 2) . Cr2 Ϫ/Ϫ mice displayed impaired humoral responses to HSV, as observed previously (11) . This result was consistent with the loss of essential costimulatory signals provided by CD21/CD35 on B cells (1, 13) . WTBM3Cr2 Ϫ/Ϫ chimeras induced robust IgG responses that were comparable to those in WT controls through at least 10 weeks. Between weeks 10 and 13, we observed a decline in serum IgG titers from peak values in all groups. The rates of IgG loss, however, were more rapid in the WTBM3Cr2 Ϫ/Ϫ chimeric animals. By week 22, only WT mice retained significant antiviral serum IgG (approximately 35% of peak titers). These results indicated that CD21/ CD35 on radiation-resistant cells, likely stromal cells, played an important role in the maintenance of IgG responses at later times following replication-defective HSV infection.
Stromal cell CD21/CD35 is critical for IgG recall responses. To assess memory B-cell activity at late times postinfection, we boosted the mice by immunization with 5BlacZ virus and measured their ability to elicit recall responses (Fig. 4B ). To ensure a maximal recall response in these animals, we inoculated mice by the i.p. route at week 32 and collected sera at weeks 33 and 34 for ELISA analysis. WT mice primed 6 months earlier by the i.m. route responded to the i.p. boost with robust antiviral IgG titers that were greater than previous peak activity titers. Cr2 Ϫ/Ϫ mice failed to elicit significant antiviral IgG following this additional exposure. Notably, the WTBM3Cr2 Ϫ/Ϫ chimeras also failed to mount a significant recall response to this late HSV boost. These results suggested that the population of reactive memory B cells was significantly diminished in the absence of CD21/ CD35 expression on stromal cells.
Evaluation of viral persistence in inoculated mice. The previous results argued that retention of viral antigen on stromal cells, such as FDC, was necessary for long-term antibody responses. Another possible explanation for this observation was persistent viral infection in these animals. Therefore, we examined the levels of HSV DNA present in muscle tissue from two WT mice 5 months following infection with 5BlacZ using a sensitive real-time PCR assay. In duplicate assays, only very low levels of HSV DNA (two to six molecules per sample) were observed in muscle at the site of inoculation with 5BlacZ (Table 1) . HSV-2 DNA was not detected reproducibly in distal tissues from these mice (i.e., spleen and liver). Similar results were obtained following inoculation with the attenuated, replication-competent 186⌬Kpn strain, which contains a deletion of the viral thymidine kinase gene. All tissues from a mock-treated animal were negative for HSV-2 DNA in these experiments. These data indicated that neither replicating nor nonreplicating strains of HSV-2 established ongoing infection efficiently. Instead, the limited amounts of viral DNA detected are more consistent with a model in which long-term antibody responses are maintained by mechanisms other than viral persistence, such as antigen retention on FDC.
DISCUSSION
We have shown here that immunization with replicationdefective HSV-2 strains can elicit durable serum IgG responses and that antigen retention by CD21/CD35 appears to be very important for maintenance of long-term humoral immunity. We observed that the IgG response to replication-defective HSV-2 in WT mice was not static and that qualitative changes in antibody reactivity to viral proteins occurred at late times postinfection. In particular, many viral-antigen-specific IgG responses were generated at early times and were maintained over the course of 1 year postinfection. Other responses were generated early but appeared to diminish over this time. Finally, a subset of responses was enhanced at late times. This indicated that a portion of the durable antibody response to replication-defective HSV infection was due to antibody activity that was either new or significantly enhanced late after infection. Inoculation of WTBM3Cr2 Ϫ/Ϫ chimeric mice indicated that complement receptors CD21 and/or CD35 expressed on stromal cells play an important role in maintaining serum IgG titers and memory B-cell responses following immunization. Together, these results indicate that antigen retention by CD21/CD35 is a necessary component of the durable antibody response elicited by replication-defective HSV mutants.
Durable serum antibody responses to viral infection can be explained by antigen-independent mechanisms mediated by the generation of long-lived, antibody-producing PCs (34, 35) or by antigen-dependent mechanisms that require continued stimulation of memory B cells by immune complexes trapped on FDC (2, 3) that are present in the spleen or lymph node (14, 18, 22) . The continuous responses that we observed might arise by either mechanism. Similarly, the declining responses might be merely a less stable activity resulting from either turnover of short-lived PCs (34) or a loss of memory B cells due to the decay of trapped antigen or diminished B-cell stimulation (8, 15) . Therefore, the differences we detected between continuous and declining responses may indicate variation in B-cell or PC generation quantity or quality at early times following infection. The late/enhanced responses that we observed following replication-defective HSV-2 infection, however, allow us to speculate on the importance of antigen retention in this setting, because generation of new B-cell responses, expansion of existing low-magnitude populations, or ongoing IgG avidity maturation would not be expected to occur in the absence of antigen. Detection of these responses at late times provides compelling evidence that viral antigen remains accessible for an extended time following infection.
To test this hypothesis directly, we used a bone marrow chimera model. The fact that maintenance of serum IgG titers and B-cell recall activity required CD21/CD35 expression on stromal cells provides strong support for a model in which the durable immunity generated by replication-defective HSV in mice is largely antigen dependent. Association of viral proteins with FDC would allow naïve B cells to encounter antigen and/or memory B cells generated in low abundance during initial infection to reengage antigen, thereby enhancing immunity without requiring ongoing infection. In the absence of efficient FDC-mediated antigen trapping in WTBM3Cr2 Ϫ/Ϫ chimeric mice, early serum antibody titers were comparable to those in WT mice, indicating that induction of humoral responses was not altered significantly. Serum IgG titers, however, declined rapidly, and recall responses were lost in these chimeric animals, indicating specific defects in antibody and memory B-cell maintenance. Additional experiments will be required to identify the viral proteins recognized by the late/enhanced IgG responses. The predominance of these responses in purified virion lysates, however, indicates that they may be components of the virus particle. Potential candidates include the structural proteins VP19c (53 kDa) and VP22a (40 kDa) or the tegument proteins VP16 (55 kDa) and VP22 (38 kDa). It is unclear why an immune response to these proteins might differ from those of other viral antigens, though it may indicate that virus particles are preferentially captured and/or stabilized on stromal cells following acute infection. Ongoing viral infection might also provide a continued source of antigen over this extended period. We observed very low levels of viral DNA in muscle 5 months after inoculation with replication-defective HSV-2, but we did not detect viral RNA transcripts for either the ICP4 or the ICP27 immediate early proteins (data not shown) and therefore do not believe that persistent viral infection can explain the durable immunity seen in these studies. Regardless of the source of the viral proteins, our results demonstrate that complement-mediated retention of antigen by receptors CD21 and CD35 on stromal cells plays a significant role in IgG durability.
Although it could be argued that the amount of viral protein generated during a single-round infection by a replicationdefective virus is significantly reduced and that humoral responses in this context may be more dependent on complement activity, we have observed a similar dependence on complement for induction of IgG responses following WT HSV infection (11, 37, 38) . Those studies suggested that the amount of viral antigen generated during natural HSV infection is limiting or inefficiently presented to B cells without the assistance of these innate factors. Our current results are consistent with a model in which opsonization by complement protein C3 and subsequent trapping of immune complexes by CD21/CD35 on FDC are a necessary step in the maintenance of IgG responses to replication-defective HSV, indicating that optimal durable immunity is dependent on in vivo antigen retention.
In conclusion, we have shown that the serum IgG antibody response following infection with replication-defective HSV-2 is durable but not static over time. Analyses of WTBM3Cr2 Ϫ/Ϫ chimeric mice indicated that CD21/CD35 expression on radiation-resistant stromal cells was necessary to maintain serum IgG titers. Furthermore, these chimeric mice failed to mount a recall response to subsequent HSV-2 infection, indicating a severe defect in B-cell memory. Our data support a model in which antigen retention on FDC is necessary to maintain optimal serum IgG and memory B-cell responses following replication-defective HSV infection. This may allow ongoing stimulation of naïve and memory B cells and replenishment of a short-lived, antibody-producing plasma cell population. Additional experiments will be required to distinguish these possibilities. We observed only low levels of HSV-specific antibodies in Cr2 Ϫ/Ϫ mice, which were generated presumably in the absence of significant antigen trapping by stromal cells and receptor costimulation provided by Cr2 on B cells. It is apparent, however, that optimal long-term IgG responses in this experimental situation require Cr2 expression on stromal cells, which likely functions to allow viral antigen retention by FDC. A more detailed understanding of this CD21/CD35-mediated mechanism may assist in the design and development of vaccines that induce durable and protective immune responses.
